{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T18:44:45Z","timestamp":1786560285520,"version":"build-2736575974"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100019831","name":"Conselho Nacional das Funda\u00e7\u00f5es Estaduais de Amparo \u00e0 Pesquisa","doi-asserted-by":"publisher","award":["140350\/2021-7"],"award-info":[{"award-number":["140350\/2021-7"]}],"id":[{"id":"10.13039\/501100019831","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2024\/07191-0"],"award-info":[{"award-number":["2024\/07191-0"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["REMITRIBIC RED-00031-21 and APQ-00741-24"],"award-info":[{"award-number":["REMITRIBIC RED-00031-21 and APQ-00741-24"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["405751\/2023-0 and 305328\/2022-0"],"award-info":[{"award-number":["405751\/2023-0 and 305328\/2022-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003105","name":"Universidade Federal De Uberl\u00e2ndia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003105","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer is a group of diseases characterized by disordered cell proliferation and loss of tissue architecture. Breast cancer (BC) is the most common and lethal cancer among women, standing out for its molecular, histological and pathological heterogeneity. The BC tumor microenvironment (TME) is a complex ecosystem comprising transformed cells and a multitude of non-tumor cells, embedded in an altered extracellular matrix. Endothelial cells are present, driving angiogenesis, a relevant hallmark that ensures nutrition and oxygenation through the formation of new blood vessels. During this process, a complex network of molecules is released by tumor and endothelial cells, such as Vascular Endothelial Growth Factor (VEGF), that, in turn, induce cancer progression, diffusion, and metastasis. Purinergic signaling also regulates the functioning of endothelial cells involving the action of purines (ATP, ADP, UTP, UDP and adenosine) as signaling in purinergic receptors, with their concentration modulated by enzymes known as ectonucleotidases. This review aims to explore the contribution of purinergic signaling to BC angiogenesis, highlighting potential therapeutic targets currently under scientific focus. In general, the TME presents overexpression of ATP and adenosine, which stimulate endothelial cells through purinergic receptors. This stimulus promotes the formation of new vessels, mainly via the release of VEGF. Thus, purinergic signaling emerges as a central mechanism in BC angiogenesis, with potential to be explored in the development of antitumor therapies.<\/jats:p>","DOI":"10.1007\/s11302-025-10119-1","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:31:56Z","timestamp":1769149916000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The purinergic signaling interfaces in breast cancer angiogenesis"],"prefix":"10.1007","volume":"22","author":[{"given":"Fernanda Cardoso","family":"da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeferson","family":"Stabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Ribas","family":"F\u00fcrstenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaise Gon\u00e7alves","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"10119_CR1","volume-title":"Global cancer observatory: cancer today","author":"J Ferlay","year":"2024","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F (2024) Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon, France"},{"key":"10119_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"10119_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L (2020) Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol 84:106535. https:\/\/doi.org\/10.1016\/j.intimp.2020.106535","journal-title":"Int Immunopharmacol"},{"key":"10119_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01709-5","volume":"39","author":"X Jiang","year":"2020","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, Li X, Cao K, Deng H, He Y et al (2020) The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res 39:204. https:\/\/doi.org\/10.1186\/s13046-020-01709-5","journal-title":"J Exp Clin Cancer Res"},{"key":"10119_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s10238-024-01446-5","volume":"24","author":"G Elayat","year":"2024","unstructured":"Elayat G, Selim A (2024) Angiogenesis in breast cancer: insights and innovations. Clin Exp Med 24:178. https:\/\/doi.org\/10.1007\/s10238-024-01446-5","journal-title":"Clin Exp Med"},{"key":"10119_CR6","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1172\/jci137552","volume":"130","author":"EC de Heer","year":"2020","unstructured":"de Heer EC, Jalving M, Harris AL (2020) HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer. J Clin Invest 130:5074\u20135087. https:\/\/doi.org\/10.1172\/jci137552","journal-title":"J Clin Invest"},{"key":"10119_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1124\/pr.113.008029","volume":"66","author":"G Burnstock","year":"2014","unstructured":"Burnstock G, Ralevic V (2014) Purinergic signaling and blood vessels in health and disease. Pharmacol Rev 66:102\u2013192. https:\/\/doi.org\/10.1124\/pr.113.008029","journal-title":"Pharmacol Rev"},{"key":"10119_CR8","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3390\/cells9071612","volume":"9","author":"AdR Campos-Contreras","year":"2020","unstructured":"Campos-Contreras AdR, D\u00edaz-Mu\u00f1oz M, V\u00e1zquez-Cuevas FG (2020) Purinergic signaling in the hallmarks of cancer. Cells 9:1612","journal-title":"Cells"},{"key":"10119_CR9","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/sj.bjc.6604998","volume":"100","author":"SM Rumjahn","year":"2009","unstructured":"Rumjahn SM, Yokdang N, Baldwin KA, Thai J, Buxton IL (2009) Purinergic regulation of vascular endothelial growth factor signaling in angiogenesis. Br J Cancer 100:1465\u20131470. https:\/\/doi.org\/10.1038\/sj.bjc.6604998","journal-title":"Br J Cancer"},{"key":"10119_CR10","doi-asserted-by":"publisher","first-page":"14622","DOI":"10.1002\/jcp.28187","volume":"234","author":"A Soleimani","year":"2019","unstructured":"Soleimani A, Taghizadeh E, Shahsavari S, Amini Y, Rashidpour H, Azadian E, Jafari A, Parizadeh MR, Mashayekhi K, Soukhtanloo M et al (2019) CD73; a key ectonucleotidase in the development of breast cancer: recent advances and perspectives. J Cell Physiol 234:14622\u201314632. https:\/\/doi.org\/10.1002\/jcp.28187","journal-title":"J Cell Physiol"},{"key":"10119_CR11","unstructured":"Organization, WH (2024) Breast cancer. World Health Organization. http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer. Accessed 25 Jan 2025"},{"key":"10119_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast (Edinburgh, Scotland) 66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"10119_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02253-5","volume":"10","author":"Y Xu","year":"2023","unstructured":"Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q (2023) Global trends and forecasts of breast cancer incidence and deaths. Sci Data 10:334. https:\/\/doi.org\/10.1038\/s41597-023-02253-5","journal-title":"Sci Data"},{"key":"10119_CR14","unstructured":"FOUNDATION, N.B.C (2025) Breast Cancer Facts & Stats"},{"key":"10119_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3322\/caac.21718","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Miller KD (2022) Cancer statistics for African American\/Black people 2022. CA Cancer J Clin 72:202\u2013229. https:\/\/doi.org\/10.3322\/caac.21718","journal-title":"CA Cancer J Clin"},{"key":"10119_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H (2024) Breast cancer statistics 2024. CA Cancer J Clin 74:477\u2013495. https:\/\/doi.org\/10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"10119_CR17","doi-asserted-by":"publisher","unstructured":"de Araujo JB, Kerkhoff VV, de Oliveira Maciel SF, de Resende e Silva DT (2021) Targeting the purinergic pathway in breast cancer and its therapeutic applications. Purinergic Signal 17:179\u2013200. https:\/\/doi.org\/10.1007\/s11302-020-09760-9","DOI":"10.1007\/s11302-020-09760-9"},{"key":"10119_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbcan.2015.06.002","volume":"1856","author":"ME Barnard","year":"2015","unstructured":"Barnard ME, Boeke CE, Tamimi RM (2015) Established breast cancer risk factors and risk of intrinsic tumor subtypes. Biochim Biophys Acta (BBA) - Rev Cancer 1856:73\u201385. https:\/\/doi.org\/10.1016\/j.bbcan.2015.06.002","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"10119_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032542","author":"A Zannetti","year":"2023","unstructured":"Zannetti A (2023) Breast cancer: from pathophysiology to novel therapeutic approaches 2.0. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24032542","journal-title":"Int J Mol Sci"},{"key":"10119_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22:61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5","journal-title":"Breast Cancer Res"},{"key":"10119_CR21","first-page":"8500","volume":"8","author":"J Li","year":"2015","unstructured":"Li J, Chen Z, Su K, Zeng J (2015) Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol 8:8500\u20138505","journal-title":"Int J Clin Exp Pathol"},{"key":"10119_CR22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1097\/cad.0000000000000123","volume":"25","author":"GP Stathopoulos","year":"2014","unstructured":"Stathopoulos GP, Malamos NA, Markopoulos C, Polychronis A, Armakolas A, Rigatos S, Yannopoulou A, Kaparelou M, Antoniou P (2014) The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. Anticancer Drugs 25:950\u2013957. https:\/\/doi.org\/10.1097\/cad.0000000000000123","journal-title":"Anticancer Drugs"},{"key":"10119_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2147\/bctt.s340741","volume":"15","author":"A H\u00f6ller","year":"2023","unstructured":"H\u00f6ller A, Nguyen-Str\u00e4uli BD (2023) Diagnostic and prognostic biomarkers of luminal breast cancer: where are we now? Breast Cancer Targets Ther 15:525\u2013540. https:\/\/doi.org\/10.2147\/bctt.s340741","journal-title":"Breast Cancer Targets Ther"},{"key":"10119_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10549-019-05402-w","volume":"178","author":"G Viale","year":"2019","unstructured":"Viale G, Hanlon Newell AE, Walker E, Harlow G (2019) Ki-67 (30-9) scoring and differentiation of luminal A- and luminal B-like breast cancer subtypes. Breast Cancer Res Treat 178:451\u2013458. https:\/\/doi.org\/10.1007\/s10549-019-05402-w","journal-title":"Breast Cancer Res Treat"},{"key":"10119_CR25","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3892\/ol.2016.4199","volume":"11","author":"P Yuan","year":"2016","unstructured":"Yuan P, Xu B, Wang C, Zhang C, Sun M, Yuan L (2016) Ki-67 expression in luminal type breast cancer and its association with the clinicopathology of the cancer. Oncol Lett 11:2101\u20132105. https:\/\/doi.org\/10.3892\/ol.2016.4199","journal-title":"Oncol Lett"},{"issue":"Suppl 2","key":"10119_CR26","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","volume":"24","author":"A Prat","year":"2015","unstructured":"Prat A, Pineda E, Adamo B, Galv\u00e1n P, Fern\u00e1ndez A, Gaba L, D\u00edez M, Viladot M, Arance A, Mu\u00f1oz M (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast (Edinburgh, Scotland) 24(Suppl 2):S26-35. https:\/\/doi.org\/10.1016\/j.breast.2015.07.008","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"10119_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 22:101\u2013126. https:\/\/doi.org\/10.1038\/s41573-022-00579-0","journal-title":"Nat Rev Drug Discov"},{"key":"10119_CR28","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2217\/fon-2020-0504","volume":"17","author":"C Kay","year":"2021","unstructured":"Kay C, Mart\u00ednez-P\u00e9rez C (2021) Current trends in the treatment of HR+\/HER2+ breast cancer. Future Oncol 17:1665\u20131681. https:\/\/doi.org\/10.2217\/fon-2020-0504","journal-title":"Future Oncol"},{"key":"10119_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS (2022) Pathogenesis of triple-negative breast cancer. Annu Rev Pathol Mech Dis 17:181\u2013204. https:\/\/doi.org\/10.1146\/annurev-pathol-042420-093238","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10119_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15:121. https:\/\/doi.org\/10.1186\/s13045-022-01341-0","journal-title":"J Hematol Oncol"},{"key":"10119_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP (2023) Advances in systemic therapies for triple negative breast cancer. BMJ 381:e071674. https:\/\/doi.org\/10.1136\/bmj-2022-071674","journal-title":"BMJ"},{"key":"10119_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406:747\u2013752. https:\/\/doi.org\/10.1038\/35021093","journal-title":"Nature"},{"key":"10119_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Network, C.G.A.","year":"2012","unstructured":"Network, C.G.A. (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"key":"10119_CR34","doi-asserted-by":"publisher","first-page":"469251","DOI":"10.1155\/2014\/469251","volume":"2014","author":"CA Parise","year":"2014","unstructured":"Parise CA, Caggiano V (2014) Breast cancer survival defined by the ER\/PR\/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014:469251. https:\/\/doi.org\/10.1155\/2014\/469251","journal-title":"J Cancer Epidemiol"},{"key":"10119_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101466","author":"FC da Silva","year":"2023","unstructured":"da Silva FC, Brandao DC, Ferreira EA, Siqueira RP, Ferreira HSV, Da Silva Filho AA, Araujo TG (2023) Tailoring potential natural compounds for the treatment of luminal breast cancer. Pharmaceuticals (Basel, Switzerland). https:\/\/doi.org\/10.3390\/ph16101466","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"10119_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/nejm200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792. https:\/\/doi.org\/10.1056\/nejm200103153441101","journal-title":"N Engl J Med"},{"key":"10119_CR37","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Di\u00e9ras V, Hegg R, Im SA, Shaw Wright G et al (2018) Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108\u20132121. https:\/\/doi.org\/10.1056\/NEJMoa1809615","journal-title":"N Engl J Med"},{"key":"10119_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242316771","author":"MA Dom\u00ednguez-Cejudo","year":"2023","unstructured":"Dom\u00ednguez-Cejudo MA, Gil-Torralvo A, Cejuela M (2023) Targeting the tumor microenvironment in breast cancer: prognostic and predictive significance and therapeutic opportunities. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms242316771","journal-title":"Int J Mol Sci"},{"key":"10119_CR39","doi-asserted-by":"publisher","unstructured":"Wilson BE, Gorrini C, Cescon DW (2022) Breast cancer immune microenvironment: from pre-clinical models to clinical therapies. Breast Cancer Res Treat 191:257\u2013267. https:\/\/doi.org\/10.1007\/s10549-021-06431-0","DOI":"10.1007\/s10549-021-06431-0"},{"key":"10119_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, Gharibvand RS, Eskandari N (2024) Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun 44:521\u2013553. https:\/\/doi.org\/10.1002\/cac2.12539","journal-title":"Cancer Commun"},{"key":"10119_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25073642","author":"M Benvenuto","year":"2024","unstructured":"Benvenuto M, Focaccetti C (2024) Tumor microenvironment: cellular interaction and metabolic adaptations. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25073642","journal-title":"Int J Mol Sci"},{"key":"10119_CR42","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.mce.2013.06.003","volume":"382","author":"X Jiang","year":"2014","unstructured":"Jiang X, Shapiro DJ (2014) The immune system and inflammation in breast cancer. Mol Cell Endocrinol 382:673\u2013682. https:\/\/doi.org\/10.1016\/j.mce.2013.06.003","journal-title":"Mol Cell Endocrinol"},{"key":"10119_CR43","doi-asserted-by":"publisher","unstructured":"Niu T, Zhou F (2023) Inflammation and tumor microenvironment. Zhong Nan Da Xue Xue Bao Yi Xue Ban = J Cent South Univ Med Sci 48:1899\u20131913. https:\/\/doi.org\/10.11817\/j.issn.1672-7347.2023.230231","DOI":"10.11817\/j.issn.1672-7347.2023.230231"},{"issue":"2","key":"10119_CR44","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.breast.2007.07.013","volume":"16","author":"A Mantovani","year":"2007","unstructured":"Mantovani A, Marchesi F, Porta C, Sica A, Allavena P (2007) Inflammation and cancer: breast cancer as a prototype. Breast (Edinburgh, Scotland) 16(2):S27-33. https:\/\/doi.org\/10.1016\/j.breast.2007.07.013","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"10119_CR45","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1530\/erc-14-0096","volume":"22","author":"JI Murray","year":"2015","unstructured":"Murray JI, West NR, Murphy LC, Watson PH (2015) Intratumoural inflammation and endocrine resistance in breast cancer. Endocr Relat Cancer 22:R51-67. https:\/\/doi.org\/10.1530\/erc-14-0096","journal-title":"Endocr Relat Cancer"},{"key":"10119_CR46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2340\/1651-226x.2024.33008","volume":"63","author":"M Otterlei Fj\u00f8rtoft","year":"2024","unstructured":"Otterlei Fj\u00f8rtoft M, Huse K, Rye IH (2024) The tumor immune microenvironment in breast cancer progression. Acta Oncol (Stockholm, Sweden) 63:359\u2013367. https:\/\/doi.org\/10.2340\/1651-226x.2024.33008","journal-title":"Acta Oncol (Stockholm, Sweden)"},{"key":"10119_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak KGK, Vempati R, Nagaraju GP, Dasari VR, S N, Rao DN, Malla RR (2020) Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res 153:104683. https:\/\/doi.org\/10.1016\/j.phrs.2020.104683","journal-title":"Pharmacol Res"},{"key":"10119_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/ch-199234","volume":"74","author":"S Gehmert","year":"2020","unstructured":"Gehmert S, Lehoczky G, Loibl M, Jung F, Prantl L, Gehmert S (2020) Interaction between extracellular cancer matrix and stromal breast cells. Clin Hemorheol Microcirc 74:45\u201352. https:\/\/doi.org\/10.3233\/ch-199234","journal-title":"Clin Hemorheol Microcirc"},{"key":"10119_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14737159.2018.1439382","volume":"18","author":"S Mittal","year":"2018","unstructured":"Mittal S, Brown NJ, Holen I (2018) The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn 18:227\u2013243. https:\/\/doi.org\/10.1080\/14737159.2018.1439382","journal-title":"Expert Rev Mol Diagn"},{"key":"10119_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.addr.2015.12.017","volume":"97","author":"J Insua-Rodr\u00edguez","year":"2016","unstructured":"Insua-Rodr\u00edguez J, Oskarsson T (2016) The extracellular matrix in breast cancer. Adv Drug Deliv Rev 97:41\u201355. https:\/\/doi.org\/10.1016\/j.addr.2015.12.017","journal-title":"Adv Drug Deliv Rev"},{"key":"10119_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154846","volume":"251","author":"M Tufail","year":"2023","unstructured":"Tufail M (2023) Unlocking the potential of the tumor microenvironment for cancer therapy. Pathol Res Pract 251:154846. https:\/\/doi.org\/10.1016\/j.prp.2023.154846","journal-title":"Pathol Res Pract"},{"key":"10119_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188839","volume":"1878","author":"A Izadpanah","year":"2023","unstructured":"Izadpanah A, Willingham K, Chandrasekar B, Alt EU, Izadpanah R (2023) Unfolded protein response and angiogenesis in malignancies. Biochim Biophys Acta (BBA) - Rev Cancer 1878:188839. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188839","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"10119_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31764-9","volume":"13","author":"S Ma","year":"2022","unstructured":"Ma S, Zhao Y, Lee WC, Ong LT, Lee PL, Jiang Z, Oguz G, Niu Z, Liu M, Goh JY et al (2022) Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nat Commun 13:4118. https:\/\/doi.org\/10.1038\/s41467-022-31764-9","journal-title":"Nat Commun"},{"key":"10119_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-3-030-37184-5_6","volume":"1234","author":"K Sobierajska","year":"2020","unstructured":"Sobierajska K, Ciszewski WM, Sacewicz-Hofman I, Niewiarowska J (2020) Endothelial cells in the tumor microenvironment. Adv Exp Med Biol 1234:71\u201386. https:\/\/doi.org\/10.1007\/978-3-030-37184-5_6","journal-title":"Adv Exp Med Biol"},{"key":"10119_CR55","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC (2020) The tumor microenvironment. Curr Biol 30:R921-r925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081","journal-title":"Curr Biol"},{"key":"10119_CR56","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","volume":"146","author":"M Potente","year":"2011","unstructured":"Potente M, Gerhardt H, Carmeliet P (2011) Basic and therapeutic aspects of angiogenesis. Cell 146:873\u2013887. https:\/\/doi.org\/10.1016\/j.cell.2011.08.039","journal-title":"Cell"},{"key":"10119_CR57","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1007\/s00432-021-03814-0","volume":"147","author":"SM Bhat","year":"2021","unstructured":"Bhat SM, Badiger VA, Vasishta S, Chakraborty J, Prasad S, Ghosh S, Joshi MB (2021) 3D tumor angiogenesis models: recent advances and challenges. J Cancer Res Clin Oncol 147:3477\u20133494. https:\/\/doi.org\/10.1007\/s00432-021-03814-0","journal-title":"J Cancer Res Clin Oncol"},{"key":"10119_CR58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","volume":"20","author":"C Viallard","year":"2017","unstructured":"Viallard C, Larriv\u00e9e B (2017) Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 20:409\u2013426. https:\/\/doi.org\/10.1007\/s10456-017-9562-9","journal-title":"Angiogenesis"},{"key":"10119_CR59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-030-16908-4_3","volume":"1147","author":"J Kim","year":"2019","unstructured":"Kim J (2019) Pericytes in breast cancer. Adv Exp Med Biol 1147:93\u2013107. https:\/\/doi.org\/10.1007\/978-3-030-16908-4_3","journal-title":"Adv Exp Med Biol"},{"key":"10119_CR60","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3892\/ol.2018.8733","volume":"16","author":"T Li","year":"2018","unstructured":"Li T, Kang G, Wang T, Huang H (2018) Tumor angiogenesis and anti-angiogenic gene therapy for cancer. Oncol Lett 16:687\u2013702. https:\/\/doi.org\/10.3892\/ol.2018.8733","journal-title":"Oncol Lett"},{"key":"10119_CR61","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77:1745\u20131770. https:\/\/doi.org\/10.1007\/s00018-019-03351-7","journal-title":"Cell Mol Life Sci"},{"key":"10119_CR62","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-981-10-6020-5_8","volume":"1026","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Yao H, Hu H (2017) Disrupting tumor angiogenesis and \u201cthe hunger games\u201d for breast cancer. Adv Exp Med Biol 1026:171\u2013195. https:\/\/doi.org\/10.1007\/978-981-10-6020-5_8","journal-title":"Adv Exp Med Biol"},{"key":"10119_CR63","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/cbf.3663","volume":"39","author":"N Badodekar","year":"2021","unstructured":"Badodekar N, Sharma A, Patil V, Telang G (2021) Angiogenesis induction in breast cancer: a paracrine paradigm. Cell Biochem Funct 39:860\u2013873. https:\/\/doi.org\/10.1002\/cbf.3663","journal-title":"Cell Biochem Funct"},{"key":"10119_CR64","doi-asserted-by":"publisher","first-page":"11728","DOI":"10.3390\/ijms160511728","volume":"16","author":"L Varinska","year":"2015","unstructured":"Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J (2015) Soy and breast cancer: focus on angiogenesis. Int J Mol Sci 16:11728\u201311749. https:\/\/doi.org\/10.3390\/ijms160511728","journal-title":"Int J Mol Sci"},{"key":"10119_CR65","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/ebc20200032","volume":"65","author":"H Yan","year":"2021","unstructured":"Yan H, Bu P (2021) Non-coding RNA in cancer. Essays Biochem 65:625\u2013639. https:\/\/doi.org\/10.1042\/ebc20200032","journal-title":"Essays Biochem"},{"key":"10119_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.581007","volume":"10","author":"T Annese","year":"2020","unstructured":"Annese T, Tamma R, De Giorgis M, Ribatti D (2020) MicroRNAs biogenesis, functions and role in tumor angiogenesis. Front Oncol 10:581007. https:\/\/doi.org\/10.3389\/fonc.2020.581007","journal-title":"Front Oncol"},{"key":"10119_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01812-6","volume":"22","author":"R Liu","year":"2024","unstructured":"Liu R, Yu Y, Wang Q, Zhao Q, Yao Y, Sun M, Zhuang J, Sun C, Qi Y (2024) Interactions between hedgehog signaling pathway and the complex tumor microenvironment in breast cancer: current knowledge and therapeutic promises. Cell Commun Signal 22:432. https:\/\/doi.org\/10.1186\/s12964-024-01812-6","journal-title":"Cell Commun Signal"},{"key":"10119_CR68","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/s41388-020-01588-2","volume":"40","author":"H Yousefi","year":"2021","unstructured":"Yousefi H, Vatanmakanian M, Mahdiannasser M, Mashouri L, Alahari NV, Monjezi MR, Ilbeigi S (2021) Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance. Oncogene 40:1043\u20131063. https:\/\/doi.org\/10.1038\/s41388-020-01588-2","journal-title":"Oncogene"},{"key":"10119_CR69","doi-asserted-by":"publisher","first-page":"41717","DOI":"10.18632\/oncotarget.16684","volume":"8","author":"Y Jia","year":"2017","unstructured":"Jia Y, Chen Y, Wang Q, Jayasinghe U, Luo X, Wei Q, Wang J, Xiong H, Chen C, Xu B et al (2017) Exosome: emerging biomarker in breast cancer. Oncotarget 8:41717\u201341733. https:\/\/doi.org\/10.18632\/oncotarget.16684","journal-title":"Oncotarget"},{"key":"10119_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165840","author":"W Olejarz","year":"2020","unstructured":"Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T (2020) Exosomes in angiogenesis and anti-angiogenic therapy in cancers. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21165840","journal-title":"Int J Mol Sci"},{"key":"10119_CR71","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/circresaha.116.309726","volume":"120","author":"G Burnstock","year":"2017","unstructured":"Burnstock G (2017) Purinergic signaling in the cardiovascular system. Circ Res 120:207\u2013228. https:\/\/doi.org\/10.1161\/circresaha.116.309726","journal-title":"Circ Res"},{"key":"10119_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.699069","volume":"12","author":"X Yuan","year":"2021","unstructured":"Yuan X, Ferrari D, Mills T, Wang Y, Czopik A, Doursout MF, Evans SE, Idzko M, Eltzschig HK (2021) Editorial: purinergic signaling and inflammation. Front Immunol 12:699069. https:\/\/doi.org\/10.3389\/fimmu.2021.699069","journal-title":"Front Immunol"},{"key":"10119_CR73","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1113\/jphysiol.1929.sp002608","volume":"68","author":"AN Drury","year":"1929","unstructured":"Drury AN, Szent-Gy\u00f6rgyi A (1929) The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68:213\u2013237. https:\/\/doi.org\/10.1113\/jphysiol.1929.sp002608","journal-title":"J Physiol"},{"key":"10119_CR74","doi-asserted-by":"publisher","unstructured":"Burnstock G (1977) The purinergic nerve hypothesis. Ciba Foundation symposium. 48:295\u2013314. https:\/\/doi.org\/10.1002\/9780470720301.ch17","DOI":"10.1002\/9780470720301.ch17"},{"key":"10119_CR75","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s0079-6123(08)62107-x","volume":"109","author":"JA Ribeiro","year":"1996","unstructured":"Ribeiro JA, Cunha RA, Correia-de-S\u00e1 P, Sebasti\u00e3o AM (1996) Purinergic regulation of acetylcholine release. Prog Brain Res 109:231\u2013241. https:\/\/doi.org\/10.1016\/s0079-6123(08)62107-x","journal-title":"Prog Brain Res"},{"key":"10119_CR76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/0024-3205(94)00909-0","volume":"56","author":"RJ Theobald Jr","year":"1995","unstructured":"Theobald RJ Jr (1995) Purinergic and cholinergic components of bladder contractility and flow. Life Sci 56:445\u2013454. https:\/\/doi.org\/10.1016\/0024-3205(94)00909-0","journal-title":"Life Sci"},{"key":"10119_CR77","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.autneu.2015.04.007","volume":"191","author":"V Ralevic","year":"2015","unstructured":"Ralevic V, Dunn WR (2015) Purinergic transmission in blood vessels. Auton Neurosci 191:48\u201366. https:\/\/doi.org\/10.1016\/j.autneu.2015.04.007","journal-title":"Auton Neurosci"},{"key":"10119_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031207","author":"M Aslam","year":"2021","unstructured":"Aslam M, G\u00fcnd\u00fcz D, Troidl C, Heger J, Hamm CW, Schulz R (2021) Purinergic regulation of endothelial barrier function. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22031207","journal-title":"Int J Mol Sci"},{"key":"10119_CR79","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/ddr.1097","volume":"52","author":"H Zimmermann","year":"2001","unstructured":"Zimmermann H (2001) Ectonucleotidases: some recent developments and a note on nomenclature. Drug Dev Res 52:44\u201356","journal-title":"Drug Dev Res"},{"key":"10119_CR80","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/med.21888","volume":"42","author":"A Mahmood","year":"2022","unstructured":"Mahmood A, Iqbal J (2022) Purinergic receptors modulators: an emerging pharmacological tool for disease management. Med Res Rev 42:1661\u20131703. https:\/\/doi.org\/10.1002\/med.21888","journal-title":"Med Res Rev"},{"key":"10119_CR81","first-page":"457","volume":"48","author":"D Malec","year":"1996","unstructured":"Malec D (1996) Purinergic receptors. Pol J Pharmacol 48:457\u2013465","journal-title":"Pol J Pharmacol"},{"key":"10119_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151420","volume":"11","author":"P Kosza\u0142ka","year":"2016","unstructured":"Kosza\u0142ka P, Go\u0142u\u0144ska M, Urban A, Stasi\u0142oj\u0107 G, Stanis\u0142awowski M, Majewski M, Sk\u0142adanowski AC, Bigda J (2016) Specific activation of A3, A2A and A1 adenosine receptors in CD73-knockout mice affects B16F10 melanoma growth, neovascularization, angiogenesis and macrophage infiltration. PLoS ONE 11:e0151420. https:\/\/doi.org\/10.1371\/journal.pone.0151420","journal-title":"PLoS ONE"},{"key":"10119_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.109954","volume":"82","author":"SM McNeill","year":"2021","unstructured":"McNeill SM, Baltos JA, White PJ, May LT (2021) Biased agonism at adenosine receptors. Cell Signal 82:109954. https:\/\/doi.org\/10.1016\/j.cellsig.2021.109954","journal-title":"Cell Signal"},{"key":"10119_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-024-09382-z","volume":"51","author":"M Mahdizadeh","year":"2024","unstructured":"Mahdizadeh M, Heydari N, Shafiei A, Akbari H, Jafari SM (2024) Adenosine receptors in breast cancer. Mol Biol Rep 51:464. https:\/\/doi.org\/10.1007\/s11033-024-09382-z","journal-title":"Mol Biol Rep"},{"key":"10119_CR85","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.4049\/jimmunol.2001342","volume":"206","author":"CB Haas","year":"2021","unstructured":"Haas CB, Lov\u00e1szi M (2021) Ectonucleotidases in inflammation, immunity, and cancer. J Immunol 206:1983\u20131990. https:\/\/doi.org\/10.4049\/jimmunol.2001342","journal-title":"J Immunol"},{"key":"10119_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092223","author":"S Morello","year":"2021","unstructured":"Morello S, Caiazzo E (2021) Thrombo-inflammation: a focus on NTPDase1\/CD39. Cells. https:\/\/doi.org\/10.3390\/cells10092223","journal-title":"Cells"},{"key":"10119_CR87","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11302-006-9003-5","volume":"2","author":"SC Robson","year":"2006","unstructured":"Robson SC, S\u00e9vigny J, Zimmermann H (2006) The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2:409\u2013430. https:\/\/doi.org\/10.1007\/s11302-006-9003-5","journal-title":"Purinergic Signal"},{"key":"10119_CR88","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-023-09976-5","author":"JD Nu\u00f1ez-Rios","year":"2023","unstructured":"Nu\u00f1ez-Rios JD, Ulrich H, D\u00edaz-Mu\u00f1oz M, Lameu C, V\u00e1zquez-Cuevas FG (2023) Purinergic system in cancer stem cells. Purinergic Signal. https:\/\/doi.org\/10.1007\/s11302-023-09976-5","journal-title":"Purinergic Signal"},{"key":"10119_CR89","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11302-011-9282-3","volume":"8","author":"T Glaser","year":"2012","unstructured":"Glaser T, Cappellari AR, Pillat MM, Iser IC, Wink MR, Battastini AM, Ulrich H (2012) Perspectives of purinergic signaling in stem cell differentiation and tissue regeneration. Purinergic Signal 8:523\u2013537. https:\/\/doi.org\/10.1007\/s11302-011-9282-3","journal-title":"Purinergic Signal"},{"key":"10119_CR90","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11302-020-09693-3","volume":"16","author":"MS Pfaffenzeller","year":"2020","unstructured":"Pfaffenzeller MS, Franciosi MLM (2020) Purinergic signaling and tumor microenvironment in cervical cancer. Purinergic Signal 16:123\u2013135. https:\/\/doi.org\/10.1007\/s11302-020-09693-3","journal-title":"Purinergic Signal"},{"key":"10119_CR91","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11302-013-9357-4","volume":"9","author":"F Jacob","year":"2013","unstructured":"Jacob F, P\u00e9rez Novo C, Bachert C, Van Crombruggen K (2013) Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal 9:285\u2013306. https:\/\/doi.org\/10.1007\/s11302-013-9357-4","journal-title":"Purinergic Signal"},{"key":"10119_CR92","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.omto.2021.08.015","volume":"23","author":"T Wang","year":"2021","unstructured":"Wang T, Ma F, Qian HL (2021) Defueling the cancer: ATP synthase as an emerging target in cancer therapy. Mol Ther Oncolytics 23:82\u201395. https:\/\/doi.org\/10.1016\/j.omto.2021.08.015","journal-title":"Mol Ther Oncolytics"},{"key":"10119_CR93","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.canlet.2009.09.021","volume":"291","author":"IL Buxton","year":"2010","unstructured":"Buxton IL, Yokdang N, Matz RM (2010) Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis. Cancer Lett 291:131\u2013141. https:\/\/doi.org\/10.1016\/j.canlet.2009.09.021","journal-title":"Cancer Lett"},{"key":"10119_CR94","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/sj.bjc.6604019","volume":"97","author":"SM Rumjahn","year":"2007","unstructured":"Rumjahn SM, Javed MA, Wong N, Law WE, Buxton IL (2007) Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br J Cancer 97:1372\u20131380. https:\/\/doi.org\/10.1038\/sj.bjc.6604019","journal-title":"Br J Cancer"},{"key":"10119_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020597","author":"S Duan","year":"2021","unstructured":"Duan S, Nordmeier S, Byrnes AE, Buxton ILO (2021) Extracellular vesicle-mediated purinergic signaling contributes to host microenvironment plasticity and metastasis in triple negative breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22020597","journal-title":"Int J Mol Sci"},{"key":"10119_CR96","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.nano.2020.102240","volume":"29","author":"A Masjedi","year":"2020","unstructured":"Masjedi A, Ahmadi A, Ghani S, Malakotikhah F, Nabi Afjadi M, Irandoust M, Karoon Kiani F, Heydarzadeh Asl S, Atyabi F, Hassannia H et al (2020) Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy. Nanomed Nanotechnol Biol Med 29:102240. https:\/\/doi.org\/10.1016\/j.nano.2020.102240","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"10119_CR97","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1189\/jlb.3HI0514-249RR","volume":"97","author":"I Ernens","year":"2015","unstructured":"Ernens I, Bousquenaud M, Lenoir B, Devaux Y, Wagner DR (2015) Adenosine stimulates angiogenesis by up-regulating production of thrombospondin-1 by macrophages. J Leukoc Biol 97:9\u201318. https:\/\/doi.org\/10.1189\/jlb.3HI0514-249RR","journal-title":"J Leukoc Biol"},{"key":"10119_CR98","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10456-020-09728-8","volume":"23","author":"N Ludwig","year":"2020","unstructured":"Ludwig N, Yerneni SS, Azambuja JH, Gillespie DG, Menshikova EV, Jackson EK, Whiteside TL (2020) Tumor-derived exosomes promote angiogenesis via adenosine A(2B) receptor signaling. Angiogenesis 23:599\u2013610. https:\/\/doi.org\/10.1007\/s10456-020-09728-8","journal-title":"Angiogenesis"},{"key":"10119_CR99","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/onc.2016.206","volume":"36","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Adinolfi E (2017) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36:293\u2013303. https:\/\/doi.org\/10.1038\/onc.2016.206","journal-title":"Oncogene"},{"key":"10119_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947885","volume":"13","author":"H Aria","year":"2022","unstructured":"Aria H, Rezaei M, Nazem S, Daraei A, Nikfar G, Mansoori B, Bahmanyar M, Tavassoli A, Vakil MK, Mansoori Y (2022) Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: the prime suspect in cancer therapeutic resistance. Front Immunol 13:947885. https:\/\/doi.org\/10.3389\/fimmu.2022.947885","journal-title":"Front Immunol"},{"key":"10119_CR101","first-page":"58","volume":"50","author":"SM Rumjahn","year":"2007","unstructured":"Rumjahn SM, Baldwin KA, Buxton IL (2007) P2y receptor-mediated angiogenesis via vascular endothelial growth factor receptor 2 signaling. Proc West Pharmacol Soc 50:58\u201360","journal-title":"Proc West Pharmacol Soc"},{"key":"10119_CR102","doi-asserted-by":"publisher","unstructured":"Jin H, Kim HJ (2020) NLRC4, ASC and caspase-1 are inflammasome components that are mediated by P2Y(2)R activation in breast cancer cells. Int J Mol Sci 21:3337. https:\/\/doi.org\/10.3390\/ijms21093337","DOI":"10.3390\/ijms21093337"},{"key":"10119_CR103","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/bjc.2011.134","volume":"104","author":"N Yokdang","year":"2011","unstructured":"Yokdang N, Tellez JD, Tian H, Norvell J, Barsky SH, Valencik M, Buxton IL (2011) A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor signalling. Br J Cancer 104:1628\u20131640. https:\/\/doi.org\/10.1038\/bjc.2011.134","journal-title":"Br J Cancer"},{"key":"10119_CR104","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/carcin\/bgt493","volume":"35","author":"S Chadet","year":"2014","unstructured":"Chadet S, Jelassi B, Wannous R, Angoulvant D, Chevalier S, Besson P, Roger S (2014) The activation of P2Y2 receptors increases MCF-7 breast cancer cells migration through the MEK-ERK1\/2 signalling pathway. Carcinogenesis 35:1238\u20131247. https:\/\/doi.org\/10.1093\/carcin\/bgt493","journal-title":"Carcinogenesis"},{"key":"10119_CR105","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.3390\/cimb43030154","volume":"43","author":"MM Salahuddin","year":"2021","unstructured":"Salahuddin MM, Omran GA (2021) Effect of regorafenib on P2X7 receptor expression and different oncogenic signaling pathways in a human breast cancer cell line: a potential of new insight of the antitumor effects of regorafenib. Curr Issues Mol Biol 43:2199\u20132209. https:\/\/doi.org\/10.3390\/cimb43030154","journal-title":"Curr Issues Mol Biol"},{"issue":"5","key":"10119_CR106","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.4049\/jimmunol.1001298","volume":"185","author":"LM Hill","year":"2010","unstructured":"Hill LM, Gavala ML, Lenertz LY, Bertics PJ (2010) Extracellular ATP may contribute to tissue repair by rapidly stimulating purinergic receptor X7-dependent vascular endothelial growth factor release from primary human monocytes. J Immunol 185(5):3028\u20133034. https:\/\/doi.org\/10.4049\/jimmunol.1001298","journal-title":"J Immunol"},{"key":"10119_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04378-0","volume":"12","author":"A Pegoraro","year":"2021","unstructured":"Pegoraro A, De Marchi E, Ferracin M (2021) P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells. Cell Death Dis 12:1088. https:\/\/doi.org\/10.1038\/s41419-021-04378-0","journal-title":"Cell Death Dis"},{"key":"10119_CR108","doi-asserted-by":"publisher","first-page":"859","DOI":"10.7150\/thno.66274","volume":"12","author":"V Vultaggio-Poma","year":"2022","unstructured":"Vultaggio-Poma V, Falzoni S, Chiozzi P, Sarti AC, Adinolfi E, Giuliani AL, S\u00e1nchez-Melgar A, Boldrini P, Zanoni M, Tesei A et al (2022) Extracellular ATP is increased by release of ATP-loaded microparticles triggered by nutrient deprivation. Theranostics 12:859\u2013874. https:\/\/doi.org\/10.7150\/thno.66274","journal-title":"Theranostics"},{"key":"10119_CR109","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1158\/0008-5472.can-14-1259","volume":"75","author":"E Adinolfi","year":"2015","unstructured":"Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, Sarti AC, Bonora M, Syberg S, Corigliano D et al (2015) Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res 75:635\u2013644. https:\/\/doi.org\/10.1158\/0008-5472.can-14-1259","journal-title":"Cancer Res"},{"key":"10119_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.876510","volume":"10","author":"E De Marchi","year":"2022","unstructured":"De Marchi E, Pegoraro A, Turiello R, Di Virgilio F, Morello S, Adinolfi E (2022) A2A receptor contributes to tumor progression in P2X7 null mice. Front Cell Dev Biol 10:876510. https:\/\/doi.org\/10.3389\/fcell.2022.876510","journal-title":"Front Cell Dev Biol"},{"key":"10119_CR111","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3727\/000000007783629981","volume":"16","author":"M Panjehpour","year":"2007","unstructured":"Panjehpour M, Karami-Tehrani F (2007) Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res 16:575\u2013585. https:\/\/doi.org\/10.3727\/000000007783629981","journal-title":"Oncol Res"},{"key":"10119_CR112","doi-asserted-by":"publisher","unstructured":"Gao ZG, Jacobson KA (2019) A(2B) adenosine receptor and cancer. Int J Mol Sci 20:5139. https:\/\/doi.org\/10.3390\/ijms20205139","DOI":"10.3390\/ijms20205139"},{"key":"10119_CR113","first-page":"1","volume-title":"Chronobiologically targeted anticancer strategy: synergistic inhibition of CD39 and CD73 with adenosine receptor agonists","author":"IC Haskologlu","year":"2024","unstructured":"Haskologlu IC, Erdag E, Ulker D, Uludag MO, Sehirli AO, Abacioglu N (2024) Chronobiologically targeted anticancer strategy: synergistic inhibition of CD39 and CD73 with adenosine receptor agonists. Springer International Publishing, Cham, pp 1\u201322"},{"key":"10119_CR114","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-3-030-47189-7_9","volume":"1270","author":"L Antonioli","year":"2021","unstructured":"Antonioli L, Fornai M, Pellegrini C, D\u2019Antongiovanni V, Turiello R, Morello S, Hask\u00f3 G, Blandizzi C (2021) Adenosine signaling in the tumor microenvironment. Adv Exp Med Biol 1270:145\u2013167. https:\/\/doi.org\/10.1007\/978-3-030-47189-7_9","journal-title":"Adv Exp Med Biol"},{"key":"10119_CR115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262650","volume":"17","author":"AM Zahran","year":"2022","unstructured":"Zahran AM, Rayan A (2022) Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer. PLoS ONE 17:e0262650. https:\/\/doi.org\/10.1371\/journal.pone.0262650","journal-title":"PLoS ONE"},{"key":"10119_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217072","volume":"597","author":"S Xu","year":"2024","unstructured":"Xu S, Ma Y, Jiang X, Wang Q, Ma W (2024) CD39 transforming cancer therapy by modulating tumor microenvironment. Cancer Lett 597:217072. https:\/\/doi.org\/10.1016\/j.canlet.2024.217072","journal-title":"Cancer Lett"},{"key":"10119_CR117","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/imm.13832","volume":"173","author":"S Bessoles","year":"2024","unstructured":"Bessoles S, Chiron A, Sarrabayrouse G, De La Grange P, Abina AM, Hacein-Bey-Abina S (2024) Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple-negative breast cancer. Immunology 173:360\u2013380. https:\/\/doi.org\/10.1111\/imm.13832","journal-title":"Immunology"},{"key":"10119_CR118","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1161\/hc5001.100663","volume":"104","author":"C Goepfert","year":"2001","unstructured":"Goepfert C, Sundberg C, S\u00e9vigny J, Enjyoji K, Hoshi T, Csizmadia E, Robson S (2001) Disordered cellular migration and angiogenesis in cd39-null mice. Circulation 104:3109\u20133115. https:\/\/doi.org\/10.1161\/hc5001.100663","journal-title":"Circulation"},{"key":"10119_CR119","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2353\/ajpath.2007.070190","volume":"171","author":"SW Jackson","year":"2007","unstructured":"Jackson SW, Hoshi T, Wu Y, Sun X, Enjyoji K, Cszimadia E, Sundberg C, Robson SC (2007) Disordered purinergic signaling inhibits pathological angiogenesis in cd39\/Entpd1-null mice. Am J Pathol 171:1395\u20131404. https:\/\/doi.org\/10.2353\/ajpath.2007.070190","journal-title":"Am J Pathol"},{"key":"10119_CR120","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2217\/bmm-2023-0202","volume":"17","author":"C Li","year":"2023","unstructured":"Li C, Zhang L, Jin Q, Jiang H, Wu C (2023) CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker. Biomark Med 17:563\u2013576","journal-title":"Biomark Med"},{"key":"10119_CR121","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.28456","volume":"134","author":"B Allard","year":"2014","unstructured":"Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J (2014) Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer 134:1466\u20131473. https:\/\/doi.org\/10.1002\/ijc.28456","journal-title":"Int J Cancer"},{"key":"10119_CR122","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2174\/0929867321666141012172913","volume":"22","author":"E Adinolfi","year":"2015","unstructured":"Adinolfi E, Capece M, Amoroso F, De Marchi E, Franceschini A (2015) Emerging roles of P2X receptors in cancer. Curr Med Chem 22:878\u2013890. https:\/\/doi.org\/10.2174\/0929867321666141012172913","journal-title":"Curr Med Chem"},{"key":"10119_CR123","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1158\/1078-0432.ccr-0811-03","volume":"10","author":"J Spychala","year":"2004","unstructured":"Spychala J, Lazarowski E, Ostapkowicz A, Ayscue LH, Jin A, Mitchell BS (2004) Role of estrogen receptor in the regulation of ecto-5\u2019-nucleotidase and adenosine in breast cancer. Clin Cancer Res 10:708\u2013717. https:\/\/doi.org\/10.1158\/1078-0432.ccr-0811-03","journal-title":"Clin Cancer Res"},{"key":"10119_CR124","doi-asserted-by":"publisher","first-page":"1307860","DOI":"10.3389\/fphar.2023.1307860","volume":"14","author":"L Wang","year":"2023","unstructured":"Wang L, Liu WQ, Broussy S, Han B, Fang H (2023) Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis. Front Pharmacol 14:1307860. https:\/\/doi.org\/10.3389\/fphar.2023.1307860","journal-title":"Front Pharmacol"},{"key":"10119_CR125","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017","journal-title":"Cancer Treat Rev"},{"key":"10119_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01310-7","volume":"15","author":"Y Liu","year":"2022","unstructured":"Liu Y, Li Y, Wang Y, Lin C, Zhang D, Chen J, Ouyang L, Wu F, Zhang J, Chen L (2022) Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J Hematol Oncol 15:89. https:\/\/doi.org\/10.1186\/s13045-022-01310-7","journal-title":"J Hematol Oncol"},{"key":"10119_CR127","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.7150\/thno.43622","volume":"10","author":"G Zou","year":"2020","unstructured":"Zou G, Zhang X, Wang L, Li X, Xie T, Zhao J, Yan J, Wang L, Ye H, Jiao S et al (2020) Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics 10:6839\u20136853. https:\/\/doi.org\/10.7150\/thno.43622","journal-title":"Theranostics"},{"key":"10119_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0926-9","volume":"37","author":"Y Peng","year":"2018","unstructured":"Peng Y, Wang Y, Tang N, Sun D, Lan Y, Yu Z, Zhao X, Feng L, Zhang B, Jin L et al (2018) Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res 37:248. https:\/\/doi.org\/10.1186\/s13046-018-0926-9","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10119_CR129","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4049\/jimmunol.1101845","volume":"188","author":"C Cekic","year":"2012","unstructured":"Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J (2012) Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol 188(1):198\u2013205. https:\/\/doi.org\/10.4049\/jimmunol.1101845","journal-title":"J Immunol"},{"key":"10119_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42744-y","volume":"14","author":"L Buisseret","year":"2023","unstructured":"Buisseret L, Loirat D, Aftimos P, Maurer C (2023) Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial. Nat Commun 14:7018. https:\/\/doi.org\/10.1038\/s41467-023-42744-y","journal-title":"Nat Commun"},{"key":"10119_CR131","doi-asserted-by":"publisher","unstructured":"Zhang H, Feng L, de Andrade Mello P, Mao C, Near R, Csizmadia E, Chan LL, Enjyoji K, Gao W, Zhao H et al (2022) Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models. J Clin Investig 132: e157431. https:\/\/doi.org\/10.1172\/jci157431","DOI":"10.1172\/jci157431"},{"key":"10119_CR132","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004660","author":"L Sch\u00e4kel","year":"2022","unstructured":"Sch\u00e4kel L, Mirza S (2022) Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-004660","journal-title":"J Immunother Cancer"},{"key":"10119_CR133","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1002\/jcp.26743","volume":"233","author":"G Ghalamfarsa","year":"2018","unstructured":"Ghalamfarsa G, Rastegari A, Atyabi F, Hassannia H, Hojjat-Farsangi M, Ghanbari A, Anvari E, Mohammadi J, Azizi G (2018) Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. J Cell Physiol 233:7165\u20137177. https:\/\/doi.org\/10.1002\/jcp.26743","journal-title":"J Cell Physiol"},{"key":"10119_CR134","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jconrel.2021.07.021","volume":"337","author":"F Jin","year":"2021","unstructured":"Jin F, Qi J, Liu D, You Y, Shu G, Du Y, Wang J, Xu X, Ying X, Ji J et al (2021) Cancer-cell-biomimetic upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancer. J Control Release 337:90\u2013104. https:\/\/doi.org\/10.1016\/j.jconrel.2021.07.021","journal-title":"J Control Release"},{"key":"10119_CR135","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","volume":"72","author":"J Bendell","year":"2023","unstructured":"Bendell J, LoRusso P, Overman M (2023) First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother 72:2443\u20132458. https:\/\/doi.org\/10.1007\/s00262-023-03430-6","journal-title":"Cancer Immunol Immunother"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-025-10119-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-025-10119-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-025-10119-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:04:34Z","timestamp":1771884274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-025-10119-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10119"],"URL":"https:\/\/doi.org\/10.1007\/s11302-025-10119-1","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"13"}}